Somatostatin: What It Is, Its Functions, and Uses

Somatostatin is a hormone your body produces to slow things down. It acts as a widespread chemical brake, suppressing the release of other hormones, reducing acid secretion in the stomach, and dampening activity in both the gut and the brain. First discovered in the hypothalamus in the early 1970s, it turned out to be far more than a single-purpose brain chemical. Somatostatin shows up in the pancreas, the stomach lining, the intestines, and the immune system, and synthetic versions of it have become important drugs for conditions ranging from excess growth hormone to rare cancers.

Where Somatostatin Comes From

Your body does not make somatostatin in a single finished form. Cells first produce a larger precursor protein called prosomatostatin, then cut it into smaller active pieces. The two main products are somatostatin-14, a 14-amino-acid peptide, and somatostatin-28, a longer 28-amino-acid version. Which one a cell produces depends largely on where that cell sits. In the stomach and pancreas, the specialized D cells and neurons primarily process prosomatostatin all the way down to somatostatin-14. In the intestinal lining, the preferred end product is somatostatin-28.¹ These are not minor variations of the same molecule. Research on islet tumor cells has shown that somatostatin-14 and somatostatin-28 are produced through separate processing pathways from the same precursor, meaning the body can regulate each one independently.²

The conversion step from somatostatin-28 to somatostatin-14 involves a specific enzyme in the brain, an Arg-Lys esteropeptidase that was isolated from the rat brain cortex. This enzyme cleaves somatostatin-28 at a precise site to release somatostatin-14, suggesting that somatostatin-28 serves as an intermediate on the way to the shorter form in neural tissue.³ The practical upshot is that different organs have fine-tuned control over which version of somatostatin they deploy, even though every version traces back to the same gene.

How Somatostatin Talks to Cells

Somatostatin works by docking onto receptors on the surface of target cells. There are five known receptor subtypes, labeled SSTR1 through SSTR5, and they are spread across different tissues. When somatostatin binds to any of these receptors, it triggers a cascade of internal signals that generally results in the cell doing less of whatever it was doing. The downstream effects involve suppressing cyclic AMP levels, activating certain phospholipase pathways, and modulating MAP kinase signaling, all of which influence whether a cell grows, secretes hormones, or survives.⁴

The receptor subtype matters enormously for drug design. SSTR2 is the most widely targeted receptor in medicine, and structural studies have revealed exactly how somatostatin fits into its binding pocket. Four amino acid residues on the somatostatin molecule account for nearly half the total contact area with SSTR2, and all synthetic drug analogs mimic this core binding motif.⁵ That is why the major clinical drugs, octreotide and lanreotide, work so well at SSTR2 but have different profiles at other receptor subtypes. A newer analog called pasireotide was designed to hit a broader range of subtypes, and entirely non-peptide drugs like paltusotine are now being developed that mimic the critical binding motif with a small molecule instead of a peptide chain.

Controlling Growth Hormone and Metabolism

The function that put somatostatin on the map was its ability to suppress growth hormone (GH). In the hypothalamus, somatostatin acts as one half of a two-peptide control system. Growth-hormone-releasing factor (GHRF) stimulates the pituitary gland to secrete GH, while somatostatin inhibits it.⁶ The balance between these two signals determines how much GH enters the bloodstream at any given moment. This push-and-pull arrangement explains the pulsatile pattern of GH release that is normal in healthy people: GHRF drives periodic surges, and somatostatin helps shut each surge off.

In the pancreas, somatostatin’s role is equally fundamental but more nuanced. Pancreatic D cells release somatostatin locally to rein in both insulin-producing beta cells and glucagon-producing alpha cells. Recent work measuring calcium and cyclic AMP signals in individual islet cells has shown that somatostatin suppresses activity in alpha cells more strongly than in beta cells, even at the same concentration.⁷ This asymmetry matters because it means somatostatin is not simply a blanket “off switch” for the pancreas. It shapes the ratio of insulin to glucagon, influencing blood sugar regulation in a more targeted way than a simple inhibitor would.

Effects in the Gut

The gastrointestinal tract is one of the largest sources of somatostatin in the body, and for good reason. Somatostatin acts as a broad inhibitor of digestive function: it suppresses gastric acid production, slows the rhythmic contractions that push food along (peristalsis), and reduces the release of other gut hormones like gastrin and secretin.⁸ It also has anti-inflammatory effects that help maintain the intestinal barrier. Think of it as the gut’s own speed governor, keeping digestive processes from overshooting in ways that would damage the lining or waste resources.

This gut-level activity is what makes somatostatin and its analogs useful in acute gastrointestinal emergencies. In patients with liver cirrhosis, blood can back up into the veins around the esophagus, causing them to swell and sometimes rupture catastrophically. Somatostatin and octreotide reduce blood flow through these engorged vessels by constricting the splanchnic arteries that feed the portal system, while leaving overall cardiac output and systemic blood pressure relatively intact.⁹ In clinical trials comparing somatostatin and octreotide to older treatments for variceal bleeding, both achieved bleeding control in roughly 80 to 90 percent of patients within 72 hours, significantly better than the older drug combination of vasopressin plus nitroglycerin, which controlled bleeding in about 65 percent of cases over the same period.¹⁰ Octreotide has also been shown to remain effective over a 48-hour infusion period at reducing variceal blood flow and pressure.¹¹

Somatostatin in the Brain

Beyond the hypothalamus, somatostatin-producing neurons are scattered throughout the cerebral cortex, where they play a role in pain processing and neural circuit regulation. A striking finding from imaging studies in mice is that nerve injury causes the firing rates of cortical somatostatin interneurons to drop by about half, a reduction that appears within a week after injury and persists for at least a month.¹² When researchers experimentally reactivated those same interneurons, it prevented chronic pain from developing. The implication is that somatostatin neurons normally act as a brake on pain-related excitatory circuits in the cortex, and when that brake fails, chronic neuropathic pain can take hold.

The brain connection also extends to neurodegeneration. Loss of somatostatin and somatostatin-expressing neurons is a consistent feature of Alzheimer’s disease. These cells appear to be especially vulnerable to amyloid-beta toxicity, and their disappearance may sit at the center of a chain of events linking amyloid buildup to cognitive decline.¹³ One theoretical model proposes that the loss of somatostatin interneuron function creates a state of cortical hyperactivity that accelerates disease progression.¹⁴ Whether restoring somatostatin signaling could slow Alzheimer’s remains an open question, but it has become an active area of drug development research.

Immune and Anti-Inflammatory Effects

Somatostatin receptors are not exclusive to endocrine and neural tissue. Various immune cells also carry them, and the pattern of expression shifts depending on what the immune cell is doing and where it is in the body.¹⁵ This means the immune system is actively listening to somatostatin signals, not just incidentally exposed to them.

In animal experiments, somatostatin analogs have been shown to substantially reduce inflammation. When rats were given octreotide or lanreotide (under the brand name Somatulin) during experimentally induced inflammation, both the volume of inflammatory fluid and the concentration of white blood cells in that fluid dropped significantly in a dose-dependent fashion. The treatment also suppressed local levels of TNF-alpha, substance P, and corticotropin-releasing hormone, all of which are key drivers of the inflammatory response.¹⁶ These findings have raised interest in whether somatostatin analogs could have therapeutic value in inflammatory conditions beyond their current approved uses, though clinical translation in this area has been slow.

Treating Acromegaly

Acromegaly is a condition caused by a pituitary tumor that produces too much growth hormone, leading to abnormal growth of the hands, feet, and face, along with a host of metabolic problems. Because somatostatin naturally inhibits GH, synthetic analogs are a frontline treatment. The two long-acting injectable drugs, octreotide LAR and lanreotide Autogel, are given once a month and can normalize both GH and IGF-1 (the downstream marker of GH activity) in a substantial proportion of patients. With octreotide LAR at standard doses, IGF-1 levels returned to normal in roughly 38 to 85 percent of patients, while GH dropped to safe levels in about 33 to 75 percent. Lanreotide showed comparable results, with normalization rates in similar ranges.¹⁷

The wide range in those numbers reflects real variability among patients. Tumor size, receptor expression, and individual biology all influence how well someone responds. Some patients achieve complete biochemical control on a somatostatin analog alone; others need additional drugs or surgery. Resistance to somatostatin analogs is a recognized clinical challenge, driven by complex genetic and epigenetic changes in the tumor that can reduce receptor expression or alter downstream signaling over time.¹⁸

Neuroendocrine Tumors and Somatostatin-Based Oncology

Neuroendocrine tumors (NETs) are a diverse group of cancers that arise from hormone-producing cells. Many of them heavily express somatostatin receptors on their surface, which creates two separate therapeutic opportunities: using somatostatin analogs as treatment drugs, and using labeled somatostatin analogs as homing devices for imaging or radiation delivery.

As a treatment, long-acting somatostatin analog therapy is now recommended as first-line therapy for unresectable or metastatic NETs.¹⁹ Phase III trial data showed that octreotide LAR lengthens time to tumor progression in patients with well-differentiated metastatic midgut NETs, establishing that the drug has genuine antiproliferative effects beyond just controlling the hormonal symptoms these tumors produce.²⁰

For imaging, a modified somatostatin analog called DOTATATE is labeled with a radioactive gallium isotope (gallium-68) and injected into the patient before a PET/CT scan. Because the labeled molecule binds to the same somatostatin receptors that NETs overexpress, the tumors light up on the scan. This technique has become the preferred imaging method for initial diagnosis, staging, and locating unknown primary tumors when metastases have already been found.²¹ It is rapidly replacing older imaging methods as the standard of reference for detecting and characterizing NETs.²²

The same receptor-homing principle applies to treatment. By swapping gallium-68 for lutetium-177, a therapeutic beta-emitting radioactive isotope, the DOTATATE molecule becomes a guided missile that delivers radiation directly to tumor cells while largely sparing normal tissue. This approach, called peptide receptor radionuclide therapy (PRRT), has shown disease control rates of approximately 78 to 79 percent in patients with metastatic NETs across pooled studies.²³ For patients whose tumors have progressed on standard somatostatin analog therapy, PRRT offers a genuinely different mechanism of action and a meaningful chance of stabilizing or shrinking the disease.

Side Effects of Somatostatin Analog Therapy

Somatostatin analogs are generally well tolerated, but they are not free of side effects. The most common complaints include discomfort at the injection site, diarrhea, abdominal pain, nausea, and flatulence. These gastrointestinal symptoms tend to be worst in the first few months and then improve as the body adjusts, so treatment discontinuation due to side effects is relatively uncommon.²⁴

Gallstones are the most medically significant complication. Because somatostatin suppresses gallbladder contraction, bile sits in the gallbladder longer than usual and can form stones. Rates of gallstone formation in clinical studies range from about 3 to 56 percent depending on the study population and how carefully imaging was performed. In a controlled trial of lanreotide, new gallstones developed in about 15 percent of treated patients compared to just 1 percent on standard care. These stones were often numerous and small, and while many patients had no symptoms during treatment, complications tended to show up after the drug was stopped, with a median time to complications of about two and a half years after discontinuation.²⁵ That delayed pattern means patients and physicians need to stay alert for gallstone symptoms even after treatment ends.

Blood sugar changes are another concern, though the effect is usually modest and temporary. Because somatostatin suppresses both insulin and glucagon, analogs can tip blood sugar regulation in either direction depending on the patient. The newer analog pasireotide, which hits a broader range of receptor subtypes, causes more pronounced hyperglycemia than octreotide or lanreotide, to the point where glucose monitoring is a standard part of pasireotide therapy.²⁴ Real-world safety data have also flagged a link between octreotide and necrotizing enterocolitis in neonates, and between pasireotide and acute pancreatitis, though these are uncommon events.²⁶

Evolutionary Roots of the Somatostatin Family

Somatostatin is not a uniquely human molecule. Its gene family is ancient, with representatives found in every vertebrate group from jawless fish (lampreys) up through mammals. At least four distinct somatostatin gene loci exist across vertebrate species, generated by large-scale genome duplication events deep in evolutionary history. The gene that produces the somatostatin you hear about most, called SS1, is present in all vertebrates. A related gene, SS2, arose from a chromosome duplication event hundreds of millions of years ago. In placental mammals like us, the SS2 gene’s product has been given a separate name, cortistatin, but it is essentially the mammalian version of the SS2 peptide found in fish and amphibians.²⁷

Cortistatin overlaps with somatostatin in receptor binding but has distinct functions in the brain, particularly in sleep regulation and cortical activity. The fact that evolution has maintained both peptides for so long, despite their similarity, suggests each fills a role the other cannot fully replace. The somatostatin family also turns out to be related to the urotensin II family, another group of regulatory peptides, hinting at an even older common ancestor. For drug development, this evolutionary conservation is useful: it means the receptor subtypes and signaling pathways worked out in animal models are likely to translate meaningfully to human biology, which is part of why somatostatin-based drugs moved into clinical use relatively efficiently compared to many other peptide therapeutics.